Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study

TY - JOUR

T1 - Is allopurinol use associated with an excess risk of osteoporotic fracture?

T2 - A National Prescription Registry study

AU - Dennison, Elaine M

AU - Rubin, Katrine Hass

AU - Schwarz, Peter

AU - Harvey, Nicholas C

AU - Bone, Karen Walker

AU - Cooper, Cyrus

AU - Abrahamsen, Bo

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Summary: Using a Danish Register cohort of 86,039 adult new allopurinol users and propensity score matched controls, we found that gout requiring allopurinol prescription was associated with an increased fracture risk. Purpose: Gout, an acute inflammatory arthritis, is common and associated with elevated serum urate, obesity and high alcohol consumption. The mainstay of therapy is the urate-lowering agent, allopurinol. Here, we report the relationship between allopurinol prescription and fracture in a large registry population. Methods: We established a Danish Register cohort of 86,039 adult cases (new allopurinol users) and 86,039 age, sex and propensity score matched controls (not exposed to allopurinol or with a gout diagnosis), with no diagnosis of malignancy in the year prior. Results: We found a modest adjusted effect of allopurinol prescription on major osteoporotic fractures (hazard ratio (HR) 1.09, 95 % confidence interval (CI) 1.05–1.14, p = 0.04) and on hip fractures (HR 1.07, 95 % CI 1.11–1.14, p < 0.001), robust to adjustment for confounding factors (age, sex, comorbidity, medication use). Associations were stronger in men than women, and among incident allopurinol users whose gout diagnosis had been confirmed by at least one hospital contact. Prespecified subanalyses by filled dose of allopurinol (mg/day in first year of prescription) showed increased hip and major fracture risk in women in the highest allopurinol dose grouping only, while a less strong dose effect was evident for fracture rates in men. Conclusion: Gouty arthritis requiring allopurinol is associated with an excess risk of major or hip fracture, with an allopurinol dose effect evident in women such that women taking the highest doses of allopurinol—suggestive of more severe disease—were at increased risk relative to women taking lower doses.

AB - Summary: Using a Danish Register cohort of 86,039 adult new allopurinol users and propensity score matched controls, we found that gout requiring allopurinol prescription was associated with an increased fracture risk. Purpose: Gout, an acute inflammatory arthritis, is common and associated with elevated serum urate, obesity and high alcohol consumption. The mainstay of therapy is the urate-lowering agent, allopurinol. Here, we report the relationship between allopurinol prescription and fracture in a large registry population. Methods: We established a Danish Register cohort of 86,039 adult cases (new allopurinol users) and 86,039 age, sex and propensity score matched controls (not exposed to allopurinol or with a gout diagnosis), with no diagnosis of malignancy in the year prior. Results: We found a modest adjusted effect of allopurinol prescription on major osteoporotic fractures (hazard ratio (HR) 1.09, 95 % confidence interval (CI) 1.05–1.14, p = 0.04) and on hip fractures (HR 1.07, 95 % CI 1.11–1.14, p < 0.001), robust to adjustment for confounding factors (age, sex, comorbidity, medication use). Associations were stronger in men than women, and among incident allopurinol users whose gout diagnosis had been confirmed by at least one hospital contact. Prespecified subanalyses by filled dose of allopurinol (mg/day in first year of prescription) showed increased hip and major fracture risk in women in the highest allopurinol dose grouping only, while a less strong dose effect was evident for fracture rates in men. Conclusion: Gouty arthritis requiring allopurinol is associated with an excess risk of major or hip fracture, with an allopurinol dose effect evident in women such that women taking the highest doses of allopurinol—suggestive of more severe disease—were at increased risk relative to women taking lower doses.

U2 - 10.1007/s11657-015-0241-4

DO - 10.1007/s11657-015-0241-4

M3 - Journal article

C2 - 26481934

SN - 1862-3522

VL - 10

SP - 1

EP - 8

JO - Archives of Osteoporosis

JF - Archives of Osteoporosis

M1 - 36

ER -